Clinical trials: Age Related Maculopathy
Wet Age-related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- SAHARA (NCT07816289)
- Testing
- OLN324, Ranibizumab
- Volunteers
- 400 people
- Sponsor
- Ollin Biosciences, Inc.
Retinal Blood Vessels, Age-Related Macular Degeneration
Multimodal Imaging of Retinal Vessels
Retinal blood flow measurement is of scientific and clinical value. For this purpose retinal vessel morphology (such as diameter, vessel wall thickness, etc) determination is crucial.
- Trial name
- MIR (NCT02717026)
- Testing
- Optical coherence tomography, Fluorescein angiography, Fundus photography
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Graz
Age Related Macular Degeneration
Life Style and Food Habits Questionnaire in the Portuguese Population Aged 55 or More
The study population will be selected from the "Epidemiological study on the prevalence of Age related Macular Degeneration in Portugal" (Protocol N.
- Trial name
- NCT01715870
- Testing
- Life style and food habits questionnaire
- Where
- Portugal
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Neovascular Age-related Macular Degeneration (nAMD)
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
This study is a prospective, observational, non-interventional, multicenter, open-label, single arm study in patients being treated for nAMD with brolucizumab in Portugal.
- Trial name
- BLUESKY-PT (NCT04764656)
- Testing
- Brolucizumab
- Where
- 11 sites in Portugal
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Maculopathy, Age-Related
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative…
- Conditions
- Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies, Age-Related Maculopathy
- Trial name
- NCT00051129
- Testing
- Anecortave Acetate 15 mg sterile suspension, Anecortave Acetate Vehicle
- Volunteers
- 291 people
- Sponsor
- Alcon Research
Neovascular Age Related Macular Degeneration
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
This was a multicenter, open label study that is designed to evaluate the safety of brolucizumab 6 mg in a prefilled syringe in subjects with neovascular age related macular degeneration and to support collection of observations…
- Trial name
- NCT03930641
- Testing
- RTH258
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Association Between Laser Interferometric Measurement of Fundus Pulsation and Pneumotonometric Measurement of Pulsatile Ocular Blood Flow in Patients With Age-related Macular Degeneration
Several methods have been proposed for the measurement of pulsatile ocular blood flow (POBF). The pneumatic tonometer, which is commercially available, assesses POBF by measurement of intraocular pressure (IOP) changes during the…
- Trial name
- NCT00991666
- Testing
- blood flow measurement
- Where
- Austria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
AMD
Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan
Purpose To report the long-term efficacy of patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) in Changhua Christian Hospital in Taiwan.
- Trial name
- OIVAEGFFAMDIT (NCT03324542)
- Testing
- Aflibercept [Eylea]
- Where
- Taiwan
- Volunteers
- 63 people
- Sponsor
- Changhua Christian Hospital
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD)
A Study Of Early Markers Of Choroidal Neovascularization
Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of…
- Conditions
- Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
- Trial name
- NCT00902785
- Testing
- no drug
- Where
- 3 sites in Italy, Portugal and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Exudative Age-related Macular Degeneration
A Multi-Center, Open Label, Extension Study Assessing the Efficacy and Safety of Additional Intravitreal Injections of RBM-007 in Subjects With Wet Age-related Macular Degeneration
This is a multi-center, open label, extension study of NCT04200248 assessing the efficacy and safety of additional intravitreal injections of RBM-007 in subjects with wet age-related macular degeneration.
- Trial name
- RAMEN (NCT04640272)
- Testing
- RBM-007
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Ribomic USA Inc
Retinal Diseases, Macular Degeneration
Recurrence and Predictive OCT Biomarkers in Quiescent Neovascular AMD
Age-related macular degeneration (AMD) is the most common cause of severe visual impairment and blindness in elderly patients. The central part of the retina is called the macula and is very important for visual acuity.
- Conditions
- Retinal Diseases, Macular Degeneration, Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT06717139
- Where
- Sweden
- Volunteers
- 220 people
- Sponsor
- St. Erik Eye Hospital
Age Related Macular Degeneration, Geographic Atrophy
Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression
Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss worldwide, and nearly two million Australians have some signs of AMD.
- Conditions
- Age Related Macular Degeneration, Geographic Atrophy, AMD, Age-related Macular Degeneration
- Trial name
- Project AMD (NCT04739319)
- Testing
- N/A Observational study
- Where
- Australia
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Center for Eye Research Australia
Age-Related Macular Degeneration, Cataract
Age-Related Eye Disease Study (AREDS) Follow-Up
This study is a 5-year extension of the AREDS protocol, in which investigators followed the natural course of age-related macular degeneration (AMD) and cataracts.
- Trial name
- NCT00594672
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Macular Edema, Age-Related Macular Degeneration
Effect of Corona Virus on Intravitreal Injections
During pandemic of corona virus, patients compliance may be affected. We aim to study the factors lead to unregulated visits and its implications on the final visual outcome.
- Conditions
- Diabetic Macular Edema, Age-Related Macular Degeneration, Choroidal Neovascularization, Myopic Choroidal Neovascularisation
- Trial name
- NCT05494775
- Testing
- Anti-vascular endothelial growth factors (Anti-VEGFs)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Benha University
Age-Related Macular Degeneration, Polypoid Choroidal Vasculopathy
Adjunct Episcleral Brachytherapy for PCV
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate…
- Trial name
- KILAUEA (NCT05251636)
- Testing
- Episcleral Brachytherapy, Aflibercept Injection
- Volunteers
- 159 people
- Sponsor
- Salutaris Medical Devices, Inc.
Macular Degeneration, Stargardt's Macular Dystrophy
Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases
The purpose of this study was to determine the safety and therapeutic effect of sub-retinal transplantation of human embryo stem cell derived retinal pigment epitheliums (hESC-RPE) in patients with macular degeneration diseases…
- Trial name
- NCT02749734
- Testing
- Subretinal transplantation
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Southwest Hospital, China
Age-Related Macular Degeneration
Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept
A cohort of patients responsive to treatment with ranibizumab but resistant to aflibercept were identified in a previously conducted retrospective study. Identified patients will have their blood drawn for genome wide sequencing.
- Trial name
- NCT02291887
- Testing
- Ranibizumab, Aflibercept
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Associated Retinal Consultants, Michigan
Macular Pigment Optical Density
Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study
To evaluate the correlation between macular pigment optical density (MPOD) levels and risk of progression in patients with age-related macular degeneration
- Trial name
- NCT03433885
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Eye Hospital of Wenzhou Medical University
Exudative Age-related Macular Degeneration
FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration
The purpose of this study is to investigate the safety and efficacy of a combined fixed-interval and a pro re nata (PRN) regimens of ranibizumab (FUSION regimen) for the treatment of exudative age-related macular degeneration…
- Trial name
- FUSION (NCT01500915)
- Testing
- Ranibizumab
- Where
- Spain
- Volunteers
- 17 people
- Sponsor
- Institut de la Macula y la Retina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.